Sodium valproate use is associated with reduced parietal lobe thickness and brain volume ABSTRACT Objective: We hypothesized that total brain volume, white matter volume, and lobar cortical thickness would be different in epilepsy patients. We studied valproate relative to nonvalproate by using patients with epilepsy and healthy controls.
and 2012. Whole-brain T1-weighted 3D magnetization-prepared rapid acquisition with gradient echo MRI was acquired with the following acquisition parameters: echo time, 2.6 ms; repetition time, 1,900 ms; flip angle, FA 5 9°; inversion time, 900 ms; and voxel resolution, 0.9 mm isotropic.
Group B. Community-based subjects with childhood-onset epilepsy were recruited as part of the Connecticut Study of Epilepsy in Children. Cohort B was imaged when case subjects were invited to take part in a comprehensive reassessment which included a research MRI scan. Controls were recruited to represent the sex and age distribution of all cases being scanned for research purposes. Current and past antiepileptic medication use was recorded. Recruitment, characterization, and follow-up of this cohort have been described in detail elsewhere. 2, 3 Imaging was performed on a 1.5-T Siemens Sonata MRI scanner between 2008 and 2012. Whole-brain coronal T1-weighted magnetization-prepared rapid acquisition with gradient echo MRI was acquired with the following image parameters: echo time, 3.05 ms; repetition time, 1,730 ms; flip angle, 15°; inversion time, 1,100 ms; and voxel size, 0.94 3 0.94 3 1.6 mm.
All controls were neurologically normal, without any history of epilepsy, neurologic disorders, or other major medical illness. Standard clinical MRI interpretation of controls was normal.
Standard protocol approvals, registrations, and patient consents. Written informed consent of adult subjects or written parental permission and assent of minors were obtained as required by the Institutional Review Board of each site. Ethics approval for study participants was obtained from the relevant authorities, and study procedures were approved by institutional ethical standards committees on human experimentation. Image analysis. Whole-brain T1-weighted MRI was acquired for each participant. MRI scans were processed by using FreeSurfer version 5.1 (developed by the Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown). 4 Cortical thickness values were averaged over each major brain lobe (frontal, parietal, occipital, and temporal). Total brain volume and white matter volume were measured. Image processing was fully automated and masked with respect to subject allocation (disease and treatment status). The general linear model was used to investigate total brain volume, white matter volume, frontal lobe thickness, parietal lobe thickness, occipital lobe thickness, and temporal lobe thickness in subjects with epilepsy currently taking valproate relative to those not currently taking valproate and healthy controls. Age was included as a covariate in all analyses. Group A and group B analyses were conducted separately. Two-sided statistical analyses were used for the group A analysis. One-sided statistical analyses were used for the group B analysis, since the direction (increase or decrease) of any effect of valproate on volume or thickness was determined by the group A analysis.
The primary research question for this study was to determine whether sodium valproate use in epilepsy is associated with differences in total brain volume, white matter volume, and lobar cortical thickness. The study design provided Class IV evidence for these hypotheses.
We conducted a secondary analysis to determine whether past valproate use was associated with changes in brain morphometric properties. Group B nonvalproate users were subdivided into past Childhood absence epilepsy (13) Genetic generalized epilepsy (7) Focal epilepsy with known cause (9) Focal epilepsy with unknown cause (28) Parietal lobe thickness was reduced in the valproate group relative to controls and the nonvalproate epilepsy group (figure 2, mean decrease of 0.1 mm; p 5 0.0033). No thickness differences were observed in other lobes. An effect size map of the spatial distribution of thickness differences between valproate and nonvalproate subjects with epilepsy is shown in figure 3 . White matter and total brain volumes were reduced in the valproate group relative to controls and the nonvalproate epilepsy group (mean reduction of 49,924 mm 3 white matter volume, p 5 0.029; 106,859 mm 3 total brain volume; p 5 0.014).
Group B. Seven subjects with epilepsy currently taking valproate (age, 24.6 6 3.7 years), 71 subjects with epilepsy not taking valproate (age, 23 6 3.1 years), and 20 healthy controls (age, 23.3 6 3.3 years) were included. Only males were included to maintain sex matching across the 2 groups. There was no difference between 1VPA and 2VPA in the number of subjects on monotherapy compared with polytherapy (table 1, x 2 test; p 5 0.87).
The finding of reduced parietal thickness in the valproate group was confirmed in cohort B (figure 2, 0.09 mm; p 5 0.016). No significant thickness reductions were observed in the nonvalproate epilepsy group or other cortical lobes. White matter and total brain volumes were reduced in the valproate group (reductions of 37,639 mm 3 white matter volume, p 5 0.047; 50,252 mm 3 total brain volume; p 5 0.098; note p . 0.05).
No volume or cortical thickness differences were observed between past valproate users and subjects with epilepsy who had never used valproate. DISCUSSION Our study has demonstrated that valproate treatment for seizure control in epilepsy is associated with cortical thinning in the parietal lobes, along with white matter and whole brain volume reduction. It is important to note that we have confirmed these morphologic changes in an independent cohort with different epilepsy types. Our findings are consistent with pseudoatrophic brain changes associated with valproate use that have been reported in isolated epilepsy cases, 1 as well as atrophy associated with valproate use in Alzheimer disease. 5 Cerebral volume decreases have also been observed in rats exposed to valproate in utero. 6 When we compared group B past valproate users with patients with epilepsy who had never taken valproate, no significant volume or thickness differences were observed. This finding suggests that the parietal lobe thinning and volume changes we have observed in this study are transient. It is possible that the changes reported in this study are a subtle and common manifestation of the rare cases of valproate-associated encephalopathy. 1 Future longitudinal studies investigating factors that contribute to the magnitude of valproate-related morphometric changes in individuals would address this hypothesis. Examples of potential factors that could influence valproate-related atrophic brain changes are duration of valproate treatment, dose, and age (as a measure of brain maturation). The relationship between these factors and valproaterelated structural brain changes may be clinically relevant.
The parietal thickness changes identified in our study are notable in light of EEG-fMRI studies that consistently identify modified parietal lobe function during spike and wave discharges in idiopathic generalized epilepsy. [7] [8] [9] The focal epilepsy cases in group A are highly unlikely to have diffuse primary disease pathology confined to the parietal lobe. Therefore, a strength of this study is that the parietal lobe thinning we have identified is likely to be specifically related to valproate use rather than solely a result of epilepsy.
With regard to the white matter volumetric changes identified in our study, recent research 10 has described a relationship between valproate use and alterations to human CNS myelination. Our finding of white matter volume reduction associated with valproate use supports this hypothesis. MRI-based methods for investigating white matter changes by using diffusion-weighted imaging may provide further information about the relationship between valproate use and myelination.
The clinical significance of our findings lies in whether the thickness and volume changes we observed reflect an unknown but focal mechanism of action localized to the parietal lobes, and this poses the question as to whether this change is detrimental to the patient. Detrimental effects include cognitive and behavioral changes and adverse quality-of-life measures associated with valproate use. 11 The structural changes observed in our study may provide a mechanistic explanation for reported cognitive and associated changes. A particularly topical related example is impaired cognition associated with valproate exposure in utero. 12 We note that the cognitive impairments associated with fetal valproate exposure do not appear to be reversible, in contrast to the findings from the secondary analysis presented in our study. However, given that the cortex develops in a stereotypical pattern, following a posterior-to-anterior gradient into adulthood, 13 the relationship between brain maturation and the identified posterior valproate-related brain changes would be of particular interest in children and young adults.
Whether our observed effect is a direct result of valproate use or a secondary response to reduced seizures is unknown. Because our study was cross-sectional and sampling was not randomized, a causative link between valproate use and the observed neuroanatomic changes has not been fully established. A causative link between valproate use and brain volume reduction could be addressed with a prospective longitudinal study in which participants are imaged before, during, and after cessation of valproate, along with monitoring seizure frequency. Similarly, a quantitative MRI analysis of brain volume and cortical thickness associated with valproate use in nonepilepsy disorders would provide valuable information regarding our observed brain changes. Because we limited analyses to males only, there can be no confounding from sex effects on cortical thickness or brain volume measures. The main consequence of this restriction in study sample would be to limit the generalizability of the findings to females.
Pharmacologic studies of the mechanism of action of sodium valproate tend to focus on changes at a cellular level. 14 Our method was applied noninvasively in vivo over the whole brain in human subjects and demonstrated a reproducible focal effect. This may be a valuable complementary technique to understand drug action at a network or systems level.
Quantitative MRI-based analyses of brain changes are widely used in epilepsy research. These studies rarely control for medication use. By including epilepsy patients who do not take valproate as well as healthy controls in this study, we have demonstrated that antiepileptic medication has an effect on cortical thickness and brain volumes. Researchers should be aware of this potential confounding factor in studies of diseases for which valproate is a treatment. Valproate use in epilepsy is associated with parietal lobe thinning and white matter volume reduction. The surprisingly regional nature of the effect poses interesting challenges in terms of understanding drug efficacy and mechanisms of action.
